AllianceBernstein’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-638,291
| Closed | -$16M | – | 3326 |
|
|
2026
Q1 | $16M | Buy |
638,291
+603,761
| +1,749% | +$13M | 0.01% | 1016 |
|
|
2025
Q4 | $867K | Sell |
34,530
-46,075
| -57% | -$1.08M | ﹤0.01% | 2405 |
|
|
2025
Q3 | $1.82M | Buy |
80,605
+48,676
| +152% | +$1.14M | ﹤0.01% | 2056 |
|
|
2025
Q2 | $553K | Sell |
31,929
-12,983
| -29% | -$240K | ﹤0.01% | 2580 |
|
|
2025
Q1 | $982K | Buy |
44,912
+13,572
| +43% | +$375K | ﹤0.01% | 2257 |
|
|
2024
Q4 | $1M | Sell |
31,340
-9,678
| -24% | -$291K | ﹤0.01% | 2328 |
|
|
2024
Q3 | $1.18M | Buy |
41,018
+9,196
| +29% | +$341K | ﹤0.01% | 2229 |
|
|
2024
Q2 | $1.22M | Buy |
31,822
+409
| +1% | +$18.5K | ﹤0.01% | 2208 |
|
|
2024
Q1 | $1.85M | Buy |
31,413
+857
| +3% | +$54.6K | ﹤0.01% | 1960 |
|
|
2023
Q4 | $1.83M | Buy |
30,556
+1,084
| +4% | +$55K | ﹤0.01% | 1990 |
|
|
2023
Q3 | $1.12M | Sell |
29,472
-135
| -0.5% | -$5.93K | ﹤0.01% | 2177 |
|
|
2023
Q2 | $2.7M | Sell |
29,607
-81,493
| -73% | -$7.03M | ﹤0.01% | 1740 |
|
|
2023
Q1 | $7.33M | Hold |
111,100
| – | – | ﹤0.01% | 1240 |
|
|
2022
Q4 | $5.74M | Sell |
111,100
-41,824
| -27% | -$2.22M | ﹤0.01% | 1358 |
|
|
2022
Q3 | $10.4M | Sell |
152,924
-11,517
| -7% | -$682K | 0.01% | 1067 |
|
|
2022
Q2 | $7.44M | Sell |
164,441
-14,229
| -8% | -$649K | ﹤0.01% | 1260 |
|
|
2022
Q1 | $9.08M | Buy |
178,670
+98,670
| +123% | +$4.36M | ﹤0.01% | 1293 |
|
|
2021
Q4 | $3.78M | Buy |
80,000
+800
| +1% | +$31.5K | ﹤0.01% | 1774 |
|
|
2021
Q3 | $2.61M | Sell |
79,200
-900
| -1% | -$50.6K | ﹤0.01% | 2004 |
|
|
2021
Q2 | $5.06M | Hold |
80,100
| – | – | ﹤0.01% | 1606 |
|
|
2021
Q1 | $3.44M | Hold |
80,100
| – | – | ﹤0.01% | 1781 |
|
|
2020
Q4 | $4.58M | Hold |
80,100
| – | – | ﹤0.01% | 1528 |
|
|
2020
Q3 | $2.42M | Sell |
80,100
-1,600
| -2% | -$47.8K | ﹤0.01% | 1749 |
|
|
2020
Q2 | $2.67M | Buy |
81,700
+6,500
| +9% | +$209K | ﹤0.01% | 1682 |
|
|
2020
Q1 | $2.02M | Buy |
75,200
+1,500
| +2% | +$53.3K | ﹤0.01% | 1664 |
|
|
2019
Q4 | $2.26M | Hold |
73,700
| – | – | ﹤0.01% | 1891 |
|
|
2019
Q3 | $1.77M | Hold |
73,700
| – | – | ﹤0.01% | 1988 |
|
|
2019
Q2 | $1.87M | Buy |
73,700
+25,700
| +54% | +$523K | ﹤0.01% | 2015 |
|
|
2019
Q1 | $936K | Hold |
48,000
| – | – | ﹤0.01% | 2260 |
|
|
2018
Q4 | $633K | Hold |
48,000
| – | – | ﹤0.01% | 2383 |
|
|
2018
Q3 | $853K | Sell |
48,000
-54,443
| -53% | -$1.01M | ﹤0.01% | 2406 |
|
|
2018
Q2 | $2.25M | Buy |
+102,443
| New | +$2.35M | ﹤0.01% | 1827 |
|
|
2018
Q1 | – | Sell |
-85,000
| Closed | -$1.84M | – | 3022 |
|
|
2017
Q4 | $1.84M | Buy |
+85,000
| New | +$1.25M | ﹤0.01% | 1915 |
|
Other funds holding APLS
AllianceBernstein's APLS Position: Q2 2026 in Review
AllianceBernstein sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 638,291 shares — an estimated $16M sold.
AllianceBernstein first reported a position in APLS in Q4 2017 and held it in 33 quarters. The position peaked at $16M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- AllianceBernstein reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- AllianceBernstein sold 638,291 Apellis Pharmaceuticals shares in Q2 2026, an estimated $16M.
- AllianceBernstein first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 33 quarters.
- AllianceBernstein's Apellis Pharmaceuticals position peaked at $16M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.